Background: Genital infections including sexually transmitted infections (STIs) have been associated with an increased risk of HIV acquisition. Understanding how the contribution of different genital infections to HIV incidence has changed over the past two decades may be important for optimizing HIV prevention efforts. We assessed the population attributable risk percent (PAR%) of different genital tract infections, including STIs, to HIV acquisition in high-risk Kenyan women, from 1993 to 2012. Methodology: We analyzed data from HIV-1-seronegative women in the Mombasa Cohort, a prospective cohort study of women reporting trading sex for cash or in-kind payment. Monthly HIV testing was performed using ELISA. We also performed monthly evaluation for genital tract infections including vaginal yeast, bacterial vaginosis (BV), Trichomonas vaginalis, Neisseria gonorrhoeae, non-specific cervicitis, and herpes simplex virus type 2 (HSV-2). We used Cox regression models to evaluate the association between different genital tract infections and HIV acquisition over 4 time periods (1993-1997, 1998-2002, 2003-2008 and 2008-2012). Each adjusted model addressed potential confounding factors including age, hormonal contraception, place of work, sexual risk behavior, and other genital tract infections. The resulting hazard ratios were used to calculate PAR%. Results: Between 1993 and 2012, 2008 women contributed 6476 person-years of follow-up. The median age of participants at baseline was 28 years (interquartile range [IQR] 24-32). Most women worked in bars (N=1332, 66%), while the remainder worked in nightclubs (N=520, 26%) or at other venues (N=156, 8%). There were 325 incident HIV infections (incidence rate 5/100 person-years). In the overall adjusted analyses, vaginal yeast (HR 2.0; 95% confidence interval [CI] [1.6-2.6]; p=<0.001), BV (HR 1.5 95% CI [1.2-1.8], p=0.002), T. vaginalis (HR 1.5 95% CI [1.0-2.1], p=0.03), N. gonorrhoeae (HR 2.1 95% CI [1.4-3.1], p=0.001), and HSV-2 (HR 2.6 95% CI[1.5-4.3], p=<0.001) were significantly associated with increased likelihood of acquiring HIV. The overall PAR% for each infection was; vaginal yeast (6.3%), BV (10.4%), T. vaginalis (1.2%), N. gonorrhoeae (1.0%), and HSV-2 (54.6%). The PAR% for trichomoniasis and gonorrhea remained <3% and the PAR% for vaginal yeast remained <8% across the four time periods. The PAR% for BV (8.6%, 19.0%, 13.7%, 12.6%), and HSV-2 (46.0%, 70.8%, 51.2%, testing in progress for 2008-2012) were higher, but varied somewhat over time. Conclusions: Bacterial vaginosis and HSV-2 have remained the largest contributors to PAR% for HIV acquisition over the past 20 years. Interventions that prevent these conditions could provide the greatest potential benefit in terms of reducing HIV risk in women.